Clinical Trial Update: A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial combining Zilovertamab with Ibrutinib for relapsed or refractory mantle cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune System Diseases
• Immunoproliferative Disorders
• Lymphatic Diseases
• Lymphoma
• Lymphoma B-cell
• Lymphoproliferative Disorders
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Zilovertamab (zilovertamab)

Snippet

Sponsor: Oncternal Therapeutics, Inc | Conditions: Lymphoma, Mantle-Cell, Lymphoma | Phase 3 | Status: WITHDRAWN